Roivant Creates Biotech Subsidiary to Tackle Respiratory Disease

Sept. 18, 2018, 11:58 AM

Roivant Sciences Ltd., an umbrella company of biotech firms backed by Softbank Group Corp., is launching a new drugmaker to develop therapeutic treatments for serious respiratory diseases.

Called Respivant Sciences, the new company’s pipeline will be anchored by RVT-1601, a drug Roivant acquired this month from Patara Pharma Inc. It treats a cough associated with idiopathic pulmonary fibrosis, a chronic lung disease. Bill Gerhart, the former chief executive officer of now-disbanded Patara, will head the startup, Roivant said in a statement Monday.

The drug still needs approval from the U.S. Food and Drug Administration, but Roivant said early clinical trials ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.